Zacks Investment Research has recently initiated the coverage of United-Guardian, Inc. (UG) with an "Outperform" recommendation. The report highlights several compelling factors that position UG favorably in the market, making it an attractive option for investors seeking growth and stability. United-Guardian, headquartered in Hauppauge, NY, operates through its Guardian Laboratories division. The company manufactures and markets cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual ...

Financial Performance - Net sales for Q1 2024 increased to $3,254,944, a 26.7% rise from $2,570,324 in Q1 2023[13] - Net income for Q1 2024 was $925,442, up 22.4% compared to $756,081 in Q1 2023[13] - Earnings per share (basic and diluted) rose to $0.20 in Q1 2024 from $0.16 in Q1 2023, reflecting a 25% increase[13] - For the three months ended March 31, 2024, net sales reached $3,254,944, a 26.6% increase from $2,570,324 in the same period of 2023[44] - Cosmetic ingredients sales for Q1 2024 were $1,876,482, up from $761,901 in Q1 2023, indicating a substantial growth in this segment[44] - Net sales for Q1 2024 increased by $684,620 (approximately 27%) compared to Q1 2023, driven primarily by a 146% increase in cosmetic ingredients sales[85] - Net sales of pharmaceutical products decreased from $1,354,224 in Q1 2023 to $950,323 in Q1 2024, a decline of approximately 30%[86] Assets and Liabilities - Total current assets as of March 31, 2024, were $12,429,989, slightly up from $12,252,713 at December 31, 2023[15] - Cash and cash equivalents decreased to $7,073,296 from $8,243,122 at the end of 2023, a decline of 14.2%[15] - Total liabilities increased to $1,881,985 as of March 31, 2024, compared to $1,534,256 at December 31, 2023[17] - The company’s inventories totaled $1,278,691 as of March 31, 2024, compared to $1,223,506 as of December 31, 2023, showing an increase in inventory levels[54] - Working capital decreased by $150,814 to $10,567,643 at March 31, 2024, with the current ratio dropping to 6.7 to 1 from 8.0 to 1[95] Expenses - Research and development expenses decreased to $102,982 in Q1 2024 from $126,959 in Q1 2023, a reduction of 18.9%[13] - Operating expenses increased by $50,919 (approximately 10%) in Q1 2024 compared to Q1 2023, mainly due to higher Board of Directors fees and legal expenses[89] - R&D expenses decreased by $23,977 (approximately 19%) in Q1 2024 compared to Q1 2023, primarily due to lower payroll-related expenses[90] - The total provision for income taxes for the three months ended March 31, 2024, was $240,734, compared to $196,076 for the same period in 2023, representing an increase of approximately 22.7%[11] Dividends - The company declared dividends of $0.25 per share, totaling $1,148,468 for Q1 2024[19] - The Company declared a cash dividend of $0.25 per share on January 30, 2024, totaling $1,148,580, with $1,148,468 paid during the first quarter of 2024; no dividends were declared in the first quarter of 2023[67] Market and Sales - Approximately 13% of total sales in Q1 2024 were to customers outside the United States, down from 24% in Q1 2023[44] - Three pharmaceutical distributors and one cosmetic ingredient distributor accounted for 83% of gross sales and 90% of accounts receivable as of March 31, 2024, compared to 74% and 79% respectively in Q1 2023[61] - The Company had four major raw material vendors accounting for approximately 88% of raw material purchases in Q1 2024, up from 85% with three vendors in Q1 2023[62] Strategic Focus - The company is focusing on developing new products using natural and environmentally friendly raw materials[25] - The Company focuses on developing new products using natural and environmentally friendly raw materials, with its Lubrajel products certified by the COSMOS standard[75] - The Company has discontinued its line of specialty industrial products due to low sales volume and no growth prospects, effective July 1, 2023[72] Other Financial Metrics - Cash generated from operations was $644,120 in Q1 2024, up from $417,589 in Q1 2023, reflecting an increase in net income[98] - Investment income increased by $50,441 (approximately 106%) in Q1 2024, attributed to higher interest income from U.S. Treasury Bills[91] - Total accrued expenses increased to $1,422,319 as of March 31, 2024, from $1,363,044 as of December 31, 2023, reflecting a rise of approximately 4.3%[58] - The company recognized net gains on marketable securities of $41,496 for the three months ended March 31, 2024, compared to $72,701 for the same period in 2023[49] - The total marketable securities as of March 31, 2024, were valued at $1,536,336, with unrealized gains of $43,484[50] - As of March 31, 2024, the allowance for credit losses related to accounts receivable amounted to $24,321, compared to $16,672 as of December 31, 2023, reflecting a significant increase[33] - The company’s allowance for possible outdated material returns was $255,494 as of March 31, 2024, compared to $247,847 as of December 31, 2023[41]

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materia ...

Commission file number 1-10526 UNITED-GUARDIAN, INC. (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K For the transition period from _______________________ to ___________________________________________ Securities registered pursuant to Secti ...

EXHIBIT 99.1 United-Guardian Reports 2023 Financial Results HAUPPAUGE, N.Y., March 22, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net income for FY 2023 remained relatively flat compared to FY 2022. Net sales for the year decreased by 14% from $12,698,503 in 2022 to $10,885,154 in 2023, generating net income of $2,581,370 ($0.56 per share) in 2023 compared to $2,569,512 ($0.56 per share) in 2022. Donna Vigilante, President of United-Guardian, stated, "While net income remained ...

(Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Delaware 11- ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC.. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Delaware 11-1719 ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC. (Exact Name of Registrant as Specified in Its Charter) Incorporation or Organization) Delaware 11-17197 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission file number 1-10526 UNITED-GUARDIAN, INC. (Exact name of Registrant as specified in its charter) Delaware 11-1719724 (State ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 . ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 11-1719724 (State or Other Jurisd ...